Hancock Jaffe Laboratories, Inc., founded in 1999, is headquartered in Irvine, California.

Our History

The founders and senior management have pioneered and developed groundbreaking bioprosthetic devices for cardiothoracic and vascular surgery.  Several of these devices have subsequently been acquired by world-leading medical device companies and continue to provide clinical outcomes consistent with established standards of care.

Since 2007 the Company has been developing a number of innovative bioprosthetic medical devices intended to provide both state-of-the-art and new groundbreaking treatments for the most commonly performed cardiothoracic procedures — heart valve replacement and coronary artery bypass grafting — and the universally acknowledged most debilitating vascular disease of the lower limb — deep vein insufficiency.

Our Co-Founder

Norman Jaffe, Ph.D.

Norman Jaffe, Ph.D. co-founded Hancock Jaffe Laboratories, Inc. He was a leading specialist in the design, development and manufacturing of bioprosthetic devices and spent his career in the development and manufacturing of biological heart valves, vascular bioprosthetic devices and orthopedic biologic devices to augment tendon and ligament surgical procedures. He was a pioneering contributor to the development of biological heart valves and considered one of the leading experts in the world in the treatment of biological tissues and tissue engineering. Dr. Jaffe passed away in June 2016.

Major accomplishments of Dr. Jaffe included:

…collaborating with Warren Hancock to provide the first commercial biologic heart valve replacement;

…developing and manufacturing the Intact® bioprosthetic heart valve incorporating processing and design innovations to greatly improve valve function and extend valve durability decades beyond previous generations;

…developing the XCellTM heart valve bioprosthesis combining technologies that greatly reduced the “bulk” of the valve support and established the utilization of gamma radiation to both improve hemodynamic performance and achieve sterilization in normal saline, allowing for a larger valve implant with the elimination of potentially toxic packaging solutions and associated rinsing procedures;

…developing and manufacturing the ProCol® Vascular Bioprosthesis for hemodialysis access;

…developing a completely innovative patented design and technology to manufacture bioprosthetic heart valves; preclinical testing demonstrates that – for the first time – bioprosthetic valve function and performance is mimetic of a native heart valve;

…developing a small diameter vascular graft derived from a uniquely suited tissue source that in first in human studies demonstrated effectiveness as a potential substitute for artery and vein harvest;

…developing a surgically implantable bioprosthetic venous valve for venous hypertension and deep venous insufficiency.

Senior Management

Benedict Broennimann, M.D.

Chief Executive Officer

Benedict Broennimann, M.D., is a seasoned cardiovascular device executive with 20+ years experience delivering strong market, financial, and operational results for medical device companies in Europe, the US, and Asia.  Most recently he served as Chief Executive Officer and Chief Medical Officer of OstomyCure AS, where he was responsible for achieving CE marking of a Class II medical implant and leading strategic alliances and negotiations. Previously, he was chairman and Chief Executive Officer of Hancock Jaffe Laboratories and Chief Executive Officer of Leman Cardiovascular, where he spearheaded fundraising and cardiovascular device developments.  He was also Principal at Heidrick & Struggles and Highland Partners, and Senior Partner at Rosenwall Ventures, Ltd. Dr. Broennimann received his Medical Doctor Degree from the University of Bern in Switzerland, and was Chief Resident in the Department of General Surgery and Transplantation at the Centre Hospitalier Universitaire Vaudois in Lausanne, Switzerland, and is board certified in general surgery and pharmaceutical medicine.

William Abbott

Chief Financial Officer

William Abbott, with more than thirty years of experience in multi-industry international companies, was appointed Chief Financial Officer in March 2016.  Prior to joining Hancock Jaffe Laboratories, Mr. Abbott served as Vice President of Finance and Corporate Controller and later as Interim Chief Financial Officer of Apollo Medical Holdings, Inc.  Previously, Mr. Abbott served as Senior Vice President, Chief Financial Officer, Secretary and Treasurer for Cardiogenesis Corporation.  Mr. Abbott also spent six years in management positions at PepsiCo, Inc. after beginning his career with PricewaterhouseCoopers, LLP.  Mr. Abbott, who has significant public company experience, has a Bachelor of Science degree in accounting from Fairfield University and a Master in Business Administration degree from Pepperdine University.

Marc Glickman, M.D.

Chief Medical Officer

Marc H Glickman, M.D., received his Doctor of Medicine from Case Western Reserve University in Cleveland, Ohio; completed his internship and surgical residency at the University of Washington, Seattle, Washington; and finished his vascular surgery fellowship in Columbus, Ohio.  Dr. Glickman started a practice in vascular surgery in Norfolk, Virginia, developing it into the largest vascular practice in the United States and the first Vein Center in the State of Virginia.  Dr. Glickman has written over 45 articles, eight book chapters and delivered over 300 lectures worldwide.  In addition to participating in over 100 clinical trials, frequently as the principal investigator, he has been instrumental in the approval of numerous medical devices by the U.S. Food and Drug Administration.  Dr. Glickman was a founding member and past President of the Vascular Access Society of the Americas.

Sue Montoya

Vice President Operations, Quality Assurance and Regulatory Affairs

Sue Montoya has been with Hancock Jaffe Laboratories since the company was founded and is currently Vice President of Operations and QA/RA.  She has over 30 years of leadership experience with world class medical device corporations, including Shiley, Medtronic and St. Jude Medical.  As a founding employee of Xenotech Laboratories, she developed the first Quality System and Good Manufacturing Practices for Cardiovascular and Orthopedic bioprosthetic devices.  Of significant import have been her collaborative research and collaborative studies with the FDA for the sterilization of bioprostheses via gamma irradiation and an elegant clinical study evincing the efficacy of the company’s processing methodology to effectively block immunologic risks.  Additionally, Ms. Montoya has directed and furthered the company’s clinical trials, PMA Approvals, 510K and Humanitarian Use Approvals.

Medical Advisory Board Members

Antonio Gasparis, M.D.

Antonio Gasparis, M.D., is Professor of Surgery, Director of the Center for Vein Care, Director of the Wound Center, Medical Director of the Non-Invasive Vascular Laboratory, and Director of Phlebology Fellowship at Stony Brook University Medical Center. His areas of clinical interest and expertise include minimally invasive endovascular surgery for the management of aortic aneurysms; surgery for stroke prevention, aortic aneurysms, lower extremity vascular reconstruction, and dialysis access; pelvic congestion syndrome and pelvic venous insufficiency; minimally invasive percutaneous closure for varicose veins; and treatment of spider veins. Dr. Gasparis is an internationally renowned expert on venous disease and is currently a director of the 2016 New York Venous Symposium, one of the premier international conferences on issues and treatment related to venous disease. Previously, he was Committee Chair of the 2014 American Venous Forum. Dr. Gasaparis is a Fellow of the American College of Surgeons and has authored more than 35 peer-reviewed publications. He was selected for inclusion in Guide to America’s Top Surgeons by the Consumers’ Research Council of America.

Mark Meissner, M.D.

Mark Meissner, M.D., is a Professor of Surgery specializing in vascular surgery at the University of Washington School of Medicine. He has particular clinical and research interests in chronic venous disease, deep venous thrombosis, post thrombotic syndrome, venous ulceration and vascular trauma. He is the past president of the American Venous Forum, a member of the board of directors of the American College of Phlebology and a director of the Intersocietal Accreditation Commission’s Vein Center division. Dr. Meissner has published and lectured extensively on venous disease, participated in the generation of evidence-based guidelines and served as faculty at numerous medical conferences around the world. The American Board of Venous and Lymphatic Medicine and the Phlebology Leadership Institute awarded the first Venous and Lymphatic Medicine Lifetime Achievement Award to Dr. Meissner for his many important contributions to the field in the areas of research and education, and for his visionary leadership and offerings to the specialty.

Steve Elias, M.D.

Steve Elias, M.D., is Director at the Center for Vein Disease at Englewood Hospital and Medical Center. Dr. Elias has extensive expertise in vascular medicine, conducting important research and writing extensively about the treatment of vein disease, and serving as the principal investigator on several major clinical trials. His work has been recognized at national medical and scientific meetings and published in top peerreviewed journals, and he is frequently invited to lecture to both national and international audiences about minimally invasive vein care and surgical procedures. Dr. Elias has been named as one of the 25 most influential professionals in vein care worldwide by VEIN Magazine and has been recognized as Top Doctor in the New York Metropolitan Area for the past nine years by Castle Connolly. He is a member of several medical societies, including The Society for Clinical Vascular Surgery, American College of Surgeons, and the International Society of Cardiovascular Surgery.

Wade Dimitri, M.D.

Wade Dimitri, M.D., is a highly regarded cardiac surgeon in Europe and pioneer in off-pump coronary artery bypass grafting, a Council Member of the Fellowship of Postgraduate Medicine and a member of the Royal Society of Medicine. He is a reviewer for The European Journal of Cardiovascular and Thoracic Surgery. Since retiring from active clinical work, he has increased his involvement with overseas training, teaching cardiac surgeons as well as operating. At Warwick Medical School he is a member of the Panel of
Examiners. He is a member of several Cardiac Surgical Societies including The Society for Cardiothoracic
Surgery in Great Britain and Ireland, The Society of Thoracic Surgeons (USA), Scottish Cardiac Society, The
Egyptian Society Of Cardiovascular and Thoracic Surgery and an Honorary fellow of The Indian Society Of
Cardiovascular and Thoracic Surgeon. Dr Dimitri performed several dozens of surgeries with the CoreoGraft CABG graft in Europe with excellent results. He will be instrumental in helping the company bring this product to the market in Europe.

Board of Directors

Yury Zhivilo – Chairman

Yury Zhivilo has more than 30 years of international finance and trade experience. In 2004, he co-founded Leman Cardiovascular SA, now a part of Hancock Jaffe, a private company that develops, manufactures and markets innovative bioprosthetic products used in cardiovascular surgery, as well as nephrology indications. Mr. Zhivilo is a patient recipient and co-inventor of the pediatric heart valve that Hancock Jaffe is now developing and submitting for regulatory approval. Mr. Zhvillo serves on several international boards and is also President of Byodine Holding SA, which is an investor in Hancock Jaffe. He received a Senior Specialist degree in economics in 1985 from Moscow State Institute of International Affairs.

Marc H Glickman, M.D. – Director

Marc Glickman, vascular surgeon in southeast Virginia, developed the largest vascular practice in the United States and the first Vein Center in the State of Virginia. Dr. Glickman has written over 45 articles, eight book chapters and delivered over 300 lectures worldwide. In addition to participating in over 100 clinical trials, frequently as the principal investigator, he has been instrumental in the approval of numerous medical devices by the U.S. Food and Drug Administration. Dr. Glickman was a founding member and past President of the Vascular Access Society of the Americas. Dr. Glickman has been on medical advisory boards for many companies including Possis Medical, Thoratec Medical and Cohesion technolgy. He also was a board member of the Sentara Medical Group in Virginia.

Robert Anderson – Director

Robert Anderson has over 40 years of experience, including budgeting, marketing and product launches within the healthcare industry. During his career, he advanced within several healthcare companies, including CIBA, Becton Dickinson, Pfizer, Warner Lambert-Parke-Davis, Schering-Plough and Centocor. Following Mr. Anderson’s career at Parke-Davis, where he was a Group Product Director whose responsibilities included the cardiovascular products and pipeline, he became Vice-President of Marketing for the Key Pharmaceuticals division of Schering-Plough, which was responsible for the marketing of Schering Plough’s cardiovascular portfolio. Following his tenure at Schering Plough, Mr. Anderson was brought on board at Centocor to build the business infrastructure, including developing marketing plans, budgets and the US pre-launch product strategies. On a global basis his responsibilities included the cardiovascular imaging business. In 1992, Mr. Anderson joined Physicians World Communications Group (PWCG) as Vice President, was later appointed to the Executive Committee and made a Partner and was appointed Chief Operating Officer of the Company in 1997. During his tenure, PWCG grew to be the largest medical education company in the US and was responsible for the multi-year medical education effort for Lipitor. Subsequently, PWCG was acquired by Thomson Corp. in 2000. Mr. Anderson received a BA in Political Science from Rutgers University.

Robert Doyle – Director

Bob Doyle has more than 35 years of cardiovascular and strategic product launch experience having worked with companies, including Novartis, Parke-Davis, and Squibb. At Novartis he was Vice-President of Marketing Operations and also chaired the committees on PhRMA code guidelines and OIG guidelines and was a permanent member of the senior management group overseeing medical, legal and regulatory compliance. Before joining Novartis, Mr. Doyle headed marketing operations for Parke-Davis which included overall responsibility for launch meetings, including the Lipitor launch with Pfizer. Mr. Doyle continued his operations responsibilities during the Pfizer acquisition in 2000, helping to manage a $400 million annual Parke-Davis advertising and promotion budget. Mr. Doyle also served on the Board of Directors of the HMC (Healthcare Marketing & Communications) Council and in 1999 he was presented with the President’s Award. He is also a past member of the Editorial Advisory Board of Pharmaceutical Executive magazine and received their Publisher’s Award in 1999. Mr. Doyle also served as a member of the Hilton Advisory Board from 1997 to 2004. Mr. Doyle holds a Bachelor of Business Administration degree from Upsala College and an MBA from Fairleigh Dickinson University.

Gennady Alferenko – Director

Gennady Alferenko has more than 30 years of strategic financial planning and analytical experience and is presently a strategic advisor to PriceWaterhouseCoopers. His previous experience also includes serving as a Board Member of Standard Bank, JSC, a Standard Bank Group subsidiary, from 2005 to 2008, and as Senior Advisor and Director for Strategic Development for Ernst & Young from 2002–2007. From 1973 to 1985, Mr. Alferenko headed the Novosibirsk State University oil and gas research team in Eastern Siberia. In 1970, Mr. Alferenko founded Terpsichore, a ballet club that was the first community organization registered as a legal entity in the Soviet Union. He also established a network of 450 foundations that provided support to a variety of youth programs throughout that country. Since 1985 Mr. Alferenko has played important roles in advancing innovation in the USSR, Russia, and the United States. This includes establishing the Foundation for Social Inventions, an organization to facilitate the creation of open civil society in the USSR, and the US Foundation for Social Inventions which, in collaboration with its sister organization, launched the first exchange program for 100,000 US and USSR students. In 1989, he helped to coordinate Boris Yeltsin’s first visit to the United States and in 2000 he organized an initiative to establish a national “idea bank” for Russia. Mr. Alferenko studied Geology and Geophysics at Novosibirsk University.